Anterior Cruciate Ligament ReconstructionNCT06233825
Nutritional Intervention to Enhance Recovery After Arthroscopic Knee Surgery in Adults
A study testing Omega-3 Fatty Acids and Essential Amino Acids and Safflower Oil and Non-Essential Amino Acids in people with Anterior Cruciate Ligament Reconstruction and Muscular Atrophy, run by Dr. Chris McGlory, PhD at 1 site in Canada.
Trial summary
Loss of skeletal muscle mass (atrophy) and strength in the lower limb are consequences of elective knee surgery as result of prolonged disuse from limb immobilization and impaired mobility, as well as pathophysiological trauma. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Anterior Cruciate Ligament Reconstruction, Muscular Atrophy
- What is being tested?
- Omega-3 Fatty Acids and Essential Amino Acids and Safflower Oil and Non-Essential Amino Acids
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 30 participants
- Where
- 1 siteCanada
- Study dates
- 1 Feb 2024to 14 Oct 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Diagnosed anterior cruciate ligament injury requiring reconstruction surgery
- Surgery in Kingston, ON
- Patellar tendon graft, quadriceps tendon graft, or hamstring tendon graft reconstruction procedure
Who cannot join
- Any muscular, neurological, respiratory, or metabolic disease, subject to investigators' discernment, would negatively affect the subject's ability to comply with the study requirements
- Any form of cancer currently or in the last 5 years
- Bleeding disorders or antiplatelet / anticoagulation therapy
- Currently taking fish oils or within the last 6 months
- Regular consumption (≥ 2x week) of fish oil or oily fish in the last 6 months
- Allergy or sensitivity to fish, shellfish or safflower oils
Show all 13Show fewer
- Currently taking any form of steroid or within the last 6 months
- Medical inability to attain magnetic resonance imaging scans
- Known irregular responses to physical activity (e.g., shortness of breath, chest pain, dizziness, etc.)
- Surgery scheduled outside of research centre
- Scheduled surgery date < 5 weeks away
- Pregnant or plans to become pregnant within the next 6 months
- Any current illness that impacts ability to participate in protocols
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Nutritional Intervention to Enhance Recovery After Arthroscopic Knee Surgery in Adults: A Randomized Controlled Pilot Trial
Loss of skeletal muscle mass (atrophy) and strength in the lower limb are consequences of elective knee surgery as result of prolonged disuse from limb immobilization and impaired mobility, as well as pathophysiological trauma. The highest rates of skeletal muscle mass and strength loss occur during the 2-week post-surgery period, considered the early phase of outpatient recovery. Alternative to resistance exercise and pharmacology, nutritional intervention represents one strategy to combat skeletal muscle disuse atrophy.
Essential amino acids (EAA) and omega-3 fatty acids are known to independently potentiate rates of skeletal muscle protein synthesis and attenuate skeletal muscle atrophy in humans. However, the combined actions these nutritional strategies on skeletal muscle have not been explored in a pathophysiological context, such as surgery. With the ultimate goal to test the efficacy of the combined nutritional strategy to attenuate skeletal muscle disuse atrophy in the future, the aim of this present pilot study is to explore the feasibility of recruitment and retention of anterior cruciate ligament reconstruction (ACLR) outpatients from a single centre across 18 months for a 6-week nutritional intervention. Participants will consume either an intervention of omega-3 fatty acids and EAAs, or a placebo control of safflower oil and non-essential amino acids (NEAA), for 4 weeks before and 2 weeks after elective ACLR surgery. Furthermore, this pilot will characterize secondary outcomes of skeletal muscle mass, strength, and power, and integrated rates of muscle protein synthesis, as well as report participant adherence to protocols and incidence of adverse events.
Read the detailed description
Over their lifespan, many individuals experience episodes of skeletal muscle-disuse due to illness, injury, or elective surgery. Periods of prolonged skeletal muscle disuse, such after ACLR, result in the loss of skeletal muscle mass (atrophy) and strength. Skeletal muscle disuse precipitates several metabolic and functional impairments. Importantly, as the Canadian health care system shifts towards day surgeries and outpatient settings as opposed to in-hospital care, the development of patient-led strategies to mitigate skeletal muscle disuse atrophy has become increasingly vital.
For most ACLR outpatients, resistance exercise is not feasible in the immediate 2-week post-surgical period, during which the rates of skeletal muscle mass and strength loss are highest. Outside of pharmacology, nutrition represents one alternative strategy to combat skeletal muscle-disuse atrophy during this time. Previous work reported that daily supplementation with EAA prior to and after total knee arthroplasty surgery attenuated skeletal muscle atrophy and enhanced recovery of functional mobility in adults. Similarly, chronic daily supplementation with omega-3 fatty acids reduced declines in quadriceps volume in healthy, young women during single-leg immobilization. This finding complemented previous work in which supplementation with omega-3 fatty acids potentiated muscle protein synthesis rates in response to an hyperaminoacidemic-hyperinsulinemic clamp, but not fasting rates in healthy younger, middle-aged, and older adults, while it additionally improved skeletal muscle strength and power. Together, these data suggest that combined intake of omega-3 fatty acids and EAAs may be an effective strategy to combat skeletal muscle-disuse atrophy, and perhaps loss of skeletal muscle strength, in response to ACLR.
Whilst there is a growing body of literature to promote EAA and omega-3 fatty acids as anabolic stimuli, no work has explored the combined effect of these nutritional strategies in the pathophysiological context of surgery. Nutritional strategies represent an accessible treatment for skeletal muscle disuse atrophy that is independent of patient age, mobility, or current health status, which could prove favourable for surgical outpatients, as well as individuals experiencing periods of prolonged immobilization or bed rest. The future goal of this design is to test efficacy of the combined nutritional strategy of daily omega-3 fatty acid and EAA supplementation to attenuate of skeletal muscle disuse atrophy following elective knee surgery. However, the aim of the present randomized controlled pilot trial is to explore the feasibility of recruitment and retention of adult ACLR outpatients from a single centre across 18 months for a protocol that prescribes combination omega-3 fatty acid and EAA supplementation vs. a calorie- and nitrogen-matched placebo control supplement 4 weeks before and 2 weeks after ACLR surgery. This pilot will also characterize measurements of skeletal muscle volume, strength, and function, and integrated rates of skeletal muscle protein synthesis, as well as report participant adherence to protocols and the incidence of adverse events. The investigators envisage that the data generated from this trial will be used to inform the future large scale randomized controlled trial (RCT) that will examine the effect of the combined nutritional intervention on skeletal muscle volume and functional outcomes in response to ACLR. The results of future work may inform clinical practice and outpatient care guidelines to minimize loss of skeletal muscle mass and strength in response to elective surgery.
- Being tested
- Omega-3 Fatty Acids and Essential Amino Acids, Safflower Oil and Non-Essential Amino Acids
- Keywords
- omega-3 fatty acids, fish oil, eicosapentaenoic acid, docosahexaenoic acid, skeletal muscle, anterior cruciate ligament, essential amino acids, magnetic resonance imaging, muscle protein synthesis
- Medical subject headings
- Muscular Atrophy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Omega-3 Fatty Acids and Essential Amino AcidsDietary supplement
Also called Fish Oil
Oil consumed as capsules. EAA come as powder to be mixed with water before drinking. 4 g of leucine per EAA dose.
Safflower Oil and Non-Essential Amino AcidsDietary supplement
Oil consumed as capsules. NEAA are isonitrogenous to intervention condition. Both supplement types are isoenergetic to intervention. NEAA come as powder to be mixed with water before drinking.
| Study group | Role | What they receive |
|---|---|---|
| Nutritional Intervention | Experimental | 5 g omega-3 fatty acids (3.75 g eicosapentaenoic acid [EPA] + 1.25 g docosahexaenoic acid [DHA]) per day for 6 weeks, starting 4 weeks before and continuing 2 weeks after surgery, plus 40 g (2 x 20 g) of EAA per day, starting 1 week before and continuing 2 weeks after surgery. Receives: Dietary Supplement: Omega-3 Fatty Acids and Essential Amino Acids |
| Placebo Control | Placebo comparator | 5 g safflower oil per day for 6 weeks, starting 4 weeks before and continuing 2 weeks after surgery, plus 40 g (2 x 20 g) of NEAA per day, starting 1 week before and continuing 2 weeks after surgery. Receives: Dietary Supplement: Safflower Oil and Non-Essential Amino Acids |
What is being measured
The primary outcome is the main question the study is designed to answer.
Feasibility of Recruitment and Retention
Number of participants recruited and retained. Criteria for success is 30 outpatients recruited and at least 22 retained.
Measured: 18 months and 12 weeks (8 weeks post surgery), respectively.
Secondary outcomes (10)
Muscle Mass
Change in quadriceps muscle mass measured by magnetic resonance imaging scan.
Measured: 0 and 2 weeks
Muscle Cross-Sectional Area
Change in quadriceps muscle cross sectional area measured by magnetic resonance imaging scan.
Measured: 0 and 2 weeks
Muscle Protein Synthesis
Muscle protein synthesis measured as fractional synthesis rate using combined protocol of skeletal muscle biopsy, stable isotope tracing, cavity ring down spectroscopy with liquid isotope analysis, and gas-chromatography pyrolysis isotope-ratio mass spectrometry.
Measured: -1 to 0 weeks and 0 to 2 weeks.
Skeletal Muscle Phospholipid Composition
Phospholipid composition will be assessed by gas chromatography.
Measured: -4 and 2 weeks.
Erythrocyte Phospholipid Composition
Phospholipid composition will be assessed by gas chromatography.
Measured: -4 and 2 weeks.
Plasma Proteomics
Change in target signal intensity and protein concentration measured through proteome profiling by aptamer based SOMAscan assay.
Measured: -4, 0 and 2 weeks.
Expression of Translational Factors Related to Skeletal Muscle Protein Synthesis
Activation of translational factors involved in skeletal muscle protein synthesis assessed by western blotting.
Measured: -4, 0 and 2 weeks.
Muscle Function
Stair climb power test performance.
Measured: -4 and 8 weeks.
Muscle Strength
Knee-extensor peak torque measured by dynamometry.
Measured: -4 and 8 weeks.
Muscle Power
Isotonic power measured by dynamometry.
Measured: -4 and 8 weeks.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jan 2024
- Study start1 Feb 2024
- Primary completion1 Aug 2025
- Study completion14 Oct 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Anterior Cruciate Ligament ReconstructionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized controlled feasibility pilot trial.Two-arm study. Half of participants are allocated to the nutritional intervention condition (5 g omega-3, 40 g essential amino acids \[EAA\] per day), and half to the placebo control condition (5 g safflower oil, 40 g non-essential amino acids \[NEAA\] per day).
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- Dr. Chris McGlory, PhD
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Dr. Chris McGlory, PhD, Queen's University
- Investigators
- Chris McGlory, PhD, Principal investigator, Queen's University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06233825
- Sponsor's protocol ID
- 6038901
- Status last verified
- Aug 2025
- First submitted
- 19 Jan 2024
- Last updated
- 20 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Nyman DLE, Pufahl CJ, Hickey OGV, Stokes T, Simpson CA, Selinger JC, Mathur S, Janssen I, Giangregorio LM, Bardana DD, McGlory C. Nutritional intervention to enhance recovery after arthroscopic knee surgery in adults: a randomized controlled pilot trial. Pilot Feasibility Stud. 2024 Nov 12;10(1):138. doi: 10.1186/s40814-024-01561-w.
PubMed 39533408
Study at a glance
From the registry record, last updated by the sponsor on 20 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Nutritional Intervention to Enhance Recovery After Arthroscopic Knee Surgery in Adults: A Randomized Controlled Pilot Trial
- ClinicalTrials.gov ID
- NCT06233825
- Acronym / sponsor ID
- 6038901
- Keywords
- omega-3 fatty acids, fish oil, eicosapentaenoic acid, docosahexaenoic acid, skeletal muscle, anterior cruciate ligament, essential amino acids, magnetic resonance imaging
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- Dr. Chris McGlory, PhDUniversity, hospital or other
- Study start
- 1 Feb 2024 (actual)
- Primary completion
- 1 Aug 2025 (actual)
- Study completion
- 14 Oct 2025 (actual)
- First posted
- 31 Jan 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Loss of skeletal muscle mass (atrophy) and strength in the lower limb are consequences of elective knee surgery as result of prolonged disuse from limb immobilization and impaired mobility, as well as pathophysiological trauma. The highest rates of skeletal muscle mass and strength loss occur during the 2-week post-surgery period, considered the early phase of outpatient recovery. Alternative to resistance exercise and pharmacology, nutritional intervention represents one strategy to combat skeletal muscle disuse atrophy.
Essential amino acids (EAA) and omega-3 fatty acids are known to independently potentiate rates of skeletal muscle protein synthesis and attenuate skeletal muscle atrophy in humans. However, the combined actions these nutritional strategies on skeletal muscle have not been explored in a pathophysiological context, such as surgery. With the ultimate goal to test the efficacy of the combined nutritional strategy to attenuate skeletal muscle disuse atrophy in the future, the aim of this present pilot study is to explore the feasibility of recruitment and retention of anterior cruciate ligament reconstruction (ACLR) outpatients from a single centre across 18 months for a 6-week nutritional intervention. Participants will consume either an intervention of omega-3 fatty acids and EAAs, or a placebo control of safflower oil and non-essential amino acids (NEAA), for 4 weeks before and 2 weeks after elective ACLR surgery. Furthermore, this pilot will characterize secondary outcomes of skeletal muscle mass, strength, and power, and integrated rates of muscle protein synthesis, as well as report participant adherence to protocols and incidence of adverse events.
Detailed description
Over their lifespan, many individuals experience episodes of skeletal muscle-disuse due to illness, injury, or elective surgery. Periods of prolonged skeletal muscle disuse, such after ACLR, result in the loss of skeletal muscle mass (atrophy) and strength. Skeletal muscle disuse precipitates several metabolic and functional impairments. Importantly, as the Canadian health care system shifts towards day surgeries and outpatient settings as opposed to in-hospital care, the development of patient-led strategies to mitigate skeletal muscle disuse atrophy has become increasingly vital.
For most ACLR outpatients, resistance exercise is not feasible in the immediate 2-week post-surgical period, during which the rates of skeletal muscle mass and strength loss are highest. Outside of pharmacology, nutrition represents one alternative strategy to combat skeletal muscle-disuse atrophy during this time. Previous work reported that daily supplementation with EAA prior to and after total knee arthroplasty surgery attenuated skeletal muscle atrophy and enhanced recovery of functional mobility in adults. Similarly, chronic daily supplementation with omega-3 fatty acids reduced declines in quadriceps volume in healthy, young women during single-leg immobilization. This finding complemented previous work in which supplementation with omega-3 fatty acids potentiated muscle protein synthesis rates in response to an hyperaminoacidemic-hyperinsulinemic clamp, but not fasting rates in healthy younger, middle-aged, and older adults, while it additionally improved skeletal muscle strength and power. Together, these data suggest that combined intake of omega-3 fatty acids and EAAs may be an effective strategy to combat skeletal muscle-disuse atrophy, and perhaps loss of skeletal muscle strength, in response to ACLR.
Whilst there is a growing body of literature to promote EAA and omega-3 fatty acids as anabolic stimuli, no work has explored the combined effect of these nutritional strategies in the pathophysiological context of surgery. Nutritional strategies represent an accessible treatment for skeletal muscle disuse atrophy that is independent of patient age, mobility, or current health status, which could prove favourable for surgical outpatients, as well as individuals experiencing periods of prolonged immobilization or bed rest. The future goal of this design is to test efficacy of the combined nutritional strategy of daily omega-3 fatty acid and EAA supplementation to attenuate of skeletal muscle disuse atrophy following elective knee surgery. However, the aim of the present randomized controlled pilot trial is to explore the feasibility of recruitment and retention of adult ACLR outpatients from a single centre across 18 months for a protocol that prescribes combination omega-3 fatty acid and EAA supplementation vs. a calorie- and nitrogen-matched placebo control supplement 4 weeks before and 2 weeks after ACLR surgery. This pilot will also characterize measurements of skeletal muscle volume, strength, and function, and integrated rates of skeletal muscle protein synthesis, as well as report participant adherence to protocols and the incidence of adverse events. The investigators envisage that the data generated from this trial will be used to inform the future large scale randomized controlled trial (RCT) that will examine the effect of the combined nutritional intervention on skeletal muscle volume and functional outcomes in response to ACLR. The results of future work may inform clinical practice and outpatient care guidelines to minimize loss of skeletal muscle mass and strength in response to elective surgery.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Randomized controlled feasibility pilot trial.Two-arm study. Half of participants are allocated to the nutritional intervention condition (5 g omega-3, 40 g essential amino acids [EAA] per day), and half to the placebo control condition (5 g safflower oil, 40 g non-essential amino acids [NEAA] per day).
| Arm | Type | Receives |
|---|---|---|
| Nutritional Intervention | Experimental | Dietary Supplement: Omega-3 Fatty Acids and Essential Amino Acids5 g omega-3 fatty acids (3.75 g eicosapentaenoic acid [EPA] + 1.25 g docosahexaenoic acid [DHA]) per day for 6 weeks, starting 4 weeks before and continuing 2 weeks after surgery, plus 40 g (2 x 20 g) of EAA per day, starting 1 week before and continuing 2 weeks after surgery. |
| Placebo Control | Placebo comparator | Dietary Supplement: Safflower Oil and Non-Essential Amino Acids5 g safflower oil per day for 6 weeks, starting 4 weeks before and continuing 2 weeks after surgery, plus 40 g (2 x 20 g) of NEAA per day, starting 1 week before and continuing 2 weeks after surgery. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Diagnosed anterior cruciate ligament injury requiring reconstruction surgery
- Surgery in Kingston, ON
- Patellar tendon graft, quadriceps tendon graft, or hamstring tendon graft reconstruction procedure
Key exclusion criteria (13 listed)
- Any muscular, neurological, respiratory, or metabolic disease, subject to investigators' discernment, would negatively affect the subject's ability to comply with the study requirements
- Any form of cancer currently or in the last 5 years
- Bleeding disorders or antiplatelet / anticoagulation therapy
- Currently taking fish oils or within the last 6 months
- Regular consumption (≥ 2x week) of fish oil or oily fish in the last 6 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Omega-3 Fatty Acids and Essential Amino AcidsAlso: Fish OilOil consumed as capsules. EAA come as powder to be mixed with water before drinking. 4 g of leucine per EAA dose. | Dietary supplement | Nutritional Intervention |
| Safflower Oil and Non-Essential Amino AcidsOil consumed as capsules. NEAA are isonitrogenous to intervention condition. Both supplement types are isoenergetic to intervention. NEAA come as powder to be mixed with water before drinking. | Dietary supplement | Placebo Control |
Primary outcome
Feasibility of Recruitment and Retention
Time frame: 18 months and 12 weeks (8 weeks post surgery), respectively.
Number of participants recruited and retained. Criteria for success is 30 outpatients recruited and at least 22 retained.
10 secondary outcomes
Muscle Mass
Time frame: 0 and 2 weeks
Muscle Cross-Sectional Area
Time frame: 0 and 2 weeks
Muscle Protein Synthesis
Time frame: -1 to 0 weeks and 0 to 2 weeks.
Skeletal Muscle Phospholipid Composition
Time frame: -4 and 2 weeks.
Erythrocyte Phospholipid Composition
Time frame: -4 and 2 weeks.
Plasma Proteomics
Time frame: -4, 0 and 2 weeks.
Expression of Translational Factors Related to Skeletal Muscle Protein Synthesis
Time frame: -4, 0 and 2 weeks.
Muscle Function
Time frame: -4 and 8 weeks.
Muscle Strength
Time frame: -4 and 8 weeks.
Muscle Power
Time frame: -4 and 8 weeks.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Nov 2025.
- Derived from this study: PubMed 39533408Nyman DLE, Pufahl CJ, Hickey OGV, Stokes T, Simpson CA, Selinger JC, Mathur S, Janssen I, Giangregorio LM, Bardana DD, McGlory C. Nutritional intervention to enhance recovery after arthroscopic knee surgery in adults: a randomized controlled pilot trial. Pilot Feasibility Stud. 2024 Nov 12;10(1):138. doi: 10.1186/s40814-024-01561-w.
- Individual participant dataSharing planned: No
Related trials for Anterior Cruciate Ligament Reconstruction
Not yet recruiting
Stair Biomechanics and Vibration Study After ACLR
Anterior Cruciate Ligament Reconstruction (ACLR), Anterior Cruciate Ligament Injury
Not yet recruiting
Nerve Block of the Vastus Medialis and Anterior Obturator Branch in Anterior Cruciate Ligament Reconstruction With DIDT Graft
Anterior Cruciate Ligament (ACL) Reconstruction Surgery
Not yet recruiting
Supporting Athletes' Return to Sports After ACL Reconstruction: A Study of a Psychological Readiness Program
Anterior Cruciate Ligament Reconstruction, Anterior Cruciate Ligament Injuries
Recruiting
Interventions to Enhance Quadriceps Output After ACLR
ACL
Recruiting
Graded Exposure and Mindfulness Meditation for Patients Post-ACL Reconstruction
Anterior Cruciate Ligament Injuries
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Chris McGlory, PhD principal investigator
Queen's University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Omega-3 Fatty Acids and Essential Amino Acids and Safflower Oil and Non-Essential Amino Acids in people with Anterior Cruciate Ligament Reconstruction and Muscular Atrophy, run by Dr. Chris McGlory, PhD at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Feasibility of Recruitment and Retention (time frame: 18 months and 12 weeks (8 weeks post surgery), respectively.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06233825, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Nov 2025.